ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1507	National Cancer Institute	Html	en	Extragonadal Germ Cell Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of extragonadal germ cell tumors.	residual mass 0.384023 large tumor volume 0.30085 residual disease. 0.273583 recurrent testicular cancer. 0.3175 cisplatin-based chemotherapy regimens 0.371374 PDQ cancer information 0.391809 bulky tumors 0.328858 nonseminoma germ cell 0.421124 cell tumors. 0.272309 nonseminomatous germ cell 0.40313 clinical trials 0.311324 relatively small tumors 0.373793 germ cells 0.335003 particularly young individuals 0.307507 Initial chemotherapy 0.290755 cancer information summary 0.37005 breast cancer prevention 0.298248 careful testicular examination 0.334354 Initial debulking surgery 0.299396 extragonadal primary tumors 0.367991 patients 0.377174 BEP regimen 0.273424 NCI’s PDQ 0.288373 PDQ Adult Treatment 0.321273	NCI PDQ cancer 0.337916 Craniospinal radiation therapy 0.306681 extragonadal germ cell 0.679693 international germ cell 0.403901 tumor prognostic classification 0.317369 overall survival rates 0.302813 long-term disease-free survival 0.296962 chemotherapy course 0.295979 major clinical trial 0.309884 autologous bone marrow 0.294582 advanced disseminated germ 0.372421 seminomatous germ cell 0.403127 nonseminomatous extragonadal germ 0.370944 testicular seminoma 0.333059 serum alpha fetoprotein 0.309001 high-risk patients 0.281542 larger residual masses 0.321492 National Cancer Institute 0.298826 PDQ documents 0.279503 nonseminoma testicular cancer 0.332786 nonlocalized tumors 0.326576 germ cell tumors 0.92252 residual mass posttreatment 0.32699 Hematologic toxic effects 0.298226	CLICK HERE
1804	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama).	Surgical Adjuvant Breast 0.311283 node-positive breast 0.305691 susceptibility to breast 0.306299 results from 0.304936 node-negative breast carcinoma 0.307067 linfáticos internos mamarios 0.304657 invasive breast 0.310223 MammaPrint breast 0.305772 metástasis manifiesta 0.303936 Breast Cancer Family 0.311467 invasive breast carcinoma 0.30652 breast magnetic resonance 0.305716 Breast Cancer Linkage 0.318171 with node-negative breast 0.307174 brca2 mutation 0.31001 early breast 0.305558 Metástasis ipsilateral rodaderab 0.30419 Cancer Linkage Consortium 0.309543 risk factors 0.310931 ganglio centinela 0.304343 mucinous breast carcinomas 0.305818 Natl Cancer Inst 0.352497 breast carcinomas 0.328163 Women's Health Initiative 0.304548 node-negative breast 0.315228	N2b Metástasis 0.303847 from benign breast 0.306434 N2a Metástasis 0.30385 BRCA2 mutation carriers 0.309625 investigation into cancer 0.309168 Bilateral breast carcinoma 0.306729 ganglios positivos.Se 0.305633 Lancet Oncol 0.305043 contralateral breast 0.320411 lobular breast 0.305977 benign breast 0.312903 ganglio linfático centinela 0.333143 ganglios satélites 0.30541 Cancer Staging Manual 0.308858 Cancer Res Treat 0.315484 Clin Oncol 0.389208 breast carcinomas distinguish 0.305804 breast cancer 0.999811 Relat Cancer 0.305724 BRCA2-associated breast 0.305731 with invasive breast 0.307222 family history 0.30714 AJCC Cancer Staging 0.309184 Breast Cancer Res 0.348498	CLICK HERE
1832	National Cancer Institute	Html	es	Tratamiento del cáncer de vagina (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vagina.	Obstet Gynecol 0.283662 Lippincott Williams 0.242575 vagina funcional 0.243946 berek js 0.239666 Carlone M 0.228988 prognostic factors 0.719083 vaginal cancer 0.473271 Sin embargo 0.237061 American Cancer Society 0.229383 Frank SJ 0.247276 Definitive radiotherapy 0.277726 institutional experience 0.233025 Radiat Oncol Biol 0.893767 DeVita VT Jr 0.277942 Camel HM 0.230789 Jhingran A 0.245715 Gynecol Oncol 0.996446 Rosenberg SA 0.240229 primary invasive squamous 0.2365 squamous carcinoma 0.334954 Lee P 0.243278 Galakatos AE 0.229807 vagina treated with 0.406995 primary carcinoma 0.405837 Markman MA 0.223742	estadio ii 0.224737 Seski J 0.269409 vaginal intraepithelial neoplasia 0.27229 Perez CA 0.260508 Wheeler JA 0.267137 Cancer Staging Manual 0.259578 Levenback C 0.24589 Definitive irradiation 0.237883 Chen AS 0.271634 Eifel PJ 0.224915 PDQ Tratamiento 0.250686 New York 0.251038 long-term evaluation 0.231124 9th ed 0.223747 Zagars GK 0.268986 Oncol Biol Phys 0.938039 invasive squamous carcinoma 0.314957 Dundas G 0.228633 Treat Options Oncol 0.229038 cuello uterino 0.451234 Gynecol Cancer 0.242612 Twenty-year review 0.228463 AJCC Cancer Staging 0.261483 squamous cell carcinoma 0.643647	CLICK HERE
1934	National Cancer Institute	Html	es	Tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo.	siguientes procedimientos 0.506474 células madre 0.526262 pequeña cantidad 0.50899 siguientes especialistas 0.504251 siguientes tipos 0.504112 rayos x 0.523233 tejido óseo 0.519779 enlace drugs approved 0.505077 suficiente tejido 0.503088 fibroso maligno óseo 0.821835 efectos tardíos 0.529504 PDQ Efectos tardíos 0.509684 National Cancer Institute 0.502454 siguientes riesgos 0.501964 médula ósea también 0.505126	Instituto Nacional 0.509248 PDQ Tratamiento 0.523403 determinados cambios 0.501954 alta potencia 0.503883 nuevos tipos 0.503233 Physician Data Query 0.509387 cáncer óseo 0.512408 siguientes situaciones 0.505889 Bone Cancer 0.502772 siguientes enlaces 0.502451 células sanguíneas maduras 0.509706 célula madre 0.502683 siguientes pruebas 0.512226 fibroso maligno 0.960799	CLICK HERE
2079	National Cancer Institute	Html	es	BRCA1 y BRCA2: Riesgo de cáncer y pruebas genéticas	Hoja informativa acerca de los genes BRCA1 y BRCA2, de qué hacer si una persona tiene resultados positivos para una de estas alteraciones, y de las consecuencias de las pruebas genéticas.	with inherited mutations 0.40971 Fanconi anemia 0.442696 general padecerán cáncer 0.476912 Lubinski J 0.414965 Cancer Statistics Review 0.41308 brca1 or brca2 0.539593 largo plazo 0.414755 American Cancer Society 0.413258 posibles perjuicios 0.41059 Biallelic mutations 0.410182 National Comprehensive Cancer 0.413868 Breast Cancer Research 0.418728 with brca1 or 0.423664 Múltiples cánceres 0.410805 mutaciones específicas dañinas 0.471623 brca2 mutations 0.589927 among male brca1 0.421616 or genetic predisposition 0.416124 BRCA2 padecerán 0.44228 gen palb2 0.413362 BRCA1 mutation carriers 0.444383 Estados Unidos 0.427518 padecerán cáncer 0.566332 mutaciones dañinas 0.851633 PubMed Abstract 0.989166	mutation carriers identified 0.410419 seno masculino 0.429589 Clinical Oncology 0.441136 BRCA2 carriers 0.419799 risks among brca1 0.420776 BRCA2 mutation carriers 0.508942 BRCA2 mutations detected 0.422577 contralateral breast 0.413156 National Cancer Institute 0.442375 Cancer Research 0.430441 Breast Cancer Prevention 0.417323 antecedentes familiares 0.783866 or brca2 mutations 0.503006 mutation carriers with 0.423928 breast cancer 0.531052 clinical breast examination 0.410267 mujeres padecerán 0.409393 mujeres portadoras 0.421608 gen brca1 0.536899 asesoría genética 0.435987 cancer risk 0.445775 New England Journal 0.415366 bilateral profiláctica 0.437879 BRCA2 mutations account 0.4223	CLICK HERE
15908	National Cancer Institute	Html	es	Laetrilo (amigdalina) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer.	Natl Acad Sci 0.351583 institute's retrospective laetrile 0.328712 treated with laetrile 0.349302 Exp Med Surg 0.328157 Promoting poison 0.33939 antitumor activity 0.465434 cases treated with 0.28668 treatment with laetrile 0.295229 with laetrile 0.90547 CA Cancer 0.770829 Acta Unio Int 0.423146 Cancer Industry 0.474642 Med Hypotheses 0.298922 Cancer Commission 0.379224 Estados Unidos 0.752083 Amygdalin induces apoptosis 0.284053 Navarro MD 0.430756 Unio Int Contr 0.427919 Five years 0.324596 Ellison NM 0.316229 Bickis IJ 0.282987 Acad Med 0.304051 Ames MM 0.502122 Laetrile toxicity studies 0.333014 Med Assoc 0.356472	Diss Abstr Int 0.346583 years experience with 0.456942 Proc Natl Acad 0.355643 vía oral 0.317497 Laetrile toxicity 0.342269 retrospective laetrile analysis 0.331541 Cancer Establishment 0.478533 experience with laetrile 0.549066 Dorr RT 0.337868 Cancer Institute retrospective 0.411789 Unproven methods 0.542254 Treat Rep 0.798281 current status 0.343299 Intern Med 0.566133 Kovach JS 0.535271 with laetrile therapy 0.559394 Clin Nutr 0.378962 Int Contr Cancrum 0.427916 laetrile intoxication 0.281414 Moertel CG 0.440121 Herbert V 0.324024 NCI Laetrile Review 0.334924 Paxinos J 0.340814 Med Chem 0.296011	CLICK HERE
16716	National Cancer Institute	Html	en	NCI Cancer Moonshot℠ Public Access and Data Sharing Policy	NCI has established a data sharing policy that supports open, public access to all research and data for projects funded as part of the Cancer Moonshot. Find details on the policy.	Underlying Primary Data 0.835591 National Cancer Advisory 0.204571 Creative Commons 0.266314 Cancer Moonshotâ„  0.229846 Moonshot Research Project 0.326921 public domain tool 0.238273 extramural Cancer Moonshot 0.217832 Cancer Moonshot beginning 0.210573 cancer research 0.226051 Data Sharing Repositories 0.219342 underlying data 0.223365 NIH Sharing Policies 0.206938 Genomic Data Sharing 0.238331 Moonshot Research Projects 0.712789 Cancer Moonshotâ„  Research 0.221203 NIH Data Sharing 0.283755 National Cancer Institute 0.205263 Cancer Moonshot Projects 0.211704 public access 0.827988	Blue Ribbon Panel 0.23172 Cancer Moonshot Research 0.963477 independent data access 0.222133 data sharing policies 0.240205 Public Access Policy. 0.214656 nih public access 0.329101 Genomic Data Commons 0.208284 Enhanced Data Sharing 0.250631 Public Access Policy 0.237717 NCI-Supported Cancer Moonshot 0.379658 appropriate Public Access 0.254192 cancer research projects 0.217712 NCI researchers 0.205129 NCI intramural Cancer 0.231006 Data Sharing Policy 0.330676 Rule.7 Underlying Primary 0.217644 Data Sharing Plan 0.965755 intramural Cancer Moonshot 0.258314 Cancer Moonshot Public 0.244424	CLICK HERE
16839	National Cancer Institute	Html	en	Previous NCI Alliance Grantees	The NCI Alliance for Nanotechnology in Cancer has funded a multitude of research and training grants since 2005. Find here a list of all of these high impact projects.	cancer-related nanotechnology research 0.909204 initiative 0.300481 private organizations 0.515908 Focus 0.261214 National Cancer Institute 0.829641	clinical practice 0.510503 clinicians 0.293138 areas 0.260532 NCI Alliance 0.657758 major commitment 0.597371	CLICK HERE
16848	National Cancer Institute	Html	en	Treatment and Therapy	Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.	cancer treatment 0.854097 tumor type 0.82492 tumor tissues 0.889211 Cancer therapies 0.820703 large surface area 0.827043 nanoparticles 0.943843 superficial tumor 0.871555 nanotechnology cancer therapy 0.925806 multiple myeloma patients 0.821624 RNA-based genetic therapeutics 0.82576 cancer therapeutics 0.879587 vivo RNA nanoparticle 0.839578 nucleic acids 0.851966 electromagnetic radiation modalities 0.829021 cancer immunotherapy deepens 0.869884 artificial antigen 0.824529 Host Cell Response 0.906892 radiation therapy 0.999924 Standalone nanoparticle vaccines 0.835115 multiple dendritic cell 0.822099 conventional radiation therapy 0.856977 tumor vasculature permeability 0.888964 Cancer Nanotechnology Excellence 0.870289 tumor mass 0.82439	photodynamic therapy 0.836532 Cancer Nanotechnology awardees 0.958295 cancer cells 0.999243 external radiation sources 0.839028 small molecule compounds 0.820814 Cancer Therapy Center 0.956254 form Cherenkov radiation 0.829553 tumor accumulation 0.82268 atomic number nanoparticles 0.859022 Biology Cancer Center 0.860679 current radiotherapy dosage 0.82716 delivery 0.878526 combination drug delivery 0.856304 current treatment modalities 0.839227 superficial tumor sites 0.867918 innovative nanoparticle packages 0.854373 Gene silencing therapeutics 0.826818 tissue tumor targets 0.869042 electromagnetic radiation 0.829381 nanomaterial-based delivery platforms 0.862296 external electromagnetic radiation 0.823812 tumor 0.913691 tumor microenvironment 0.865684 deep tissue tumors 0.824773	CLICK HERE
17234	National Cancer Institute	Html	en	Adding Immune-based Treatments to Standard Glioblastoma Therapy	This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.	immune checkpoint inhibitor 0.991382 Dr. Gilbert 0.728039 tumor tissue 0.405841 trial contact information 0.29929 experimental vaccine 0.247456 1-year overall survival 0.300393 NCI’s Cancer 0.233291 Treating Patients 0.208707 little tumor tissue 0.376059 standard therapy plus 0.329661 immune response 0.550076 NCI Clinical Trials 0.330246 chemotherapy drug temozolomide 0.399109 cancer treatment vaccine 0.66133 primary brain tumor 0.428278 Cancer Research 0.215559 clinical trials 0.480839	slow tumor growth 0.416918 partially randomized phase 0.30891 patients 0.251176 Mark R. Gilbert 0.399405 tumor-specific vaccine 0.249165 experimental cancer treatment 0.582716 immune checkpoint inhibitors 0.542772 microscopic tumor 0.266367 newly diagnosed glioblastoma 0.842005 Current standard therapy 0.36143 placebo vaccine 0.253985 immunotherapy drug pembrolizumab 0.351275 median survival time 0.347591 protocol summary 0.359999 radiation therapy 0.342013 standard therapy 0.747186	CLICK HERE